N-Acetylcysteine in hemodialysis diabetic patients resets the activation of NF-kB in lymphomonocytes to normal values

Journal of Nephrology

Volumn 26, Issue 4, 2013, Pages 778-786

  Amore, Alessandro ^a   Formica, Marco ^b   Giacchino, Franca ^c   Gigliola, Graziella ^b   Bonello, Franco ^c   Conti, Giovanni ^a   Camilla, Roberta ^a   Coppo, Rosanna ^a  

^a REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^b ASL Cuneo 1   (Italy)

^c Civic Hospital   (Italy)

Author keywords

Antioxidants; Diabetes; Dialysis; N Acetylcysteine; NF kB; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; ADVANCED OXIDATION PROTEIN PRODUCT; DIMER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; TRANSCRIPTION FACTOR RELA;

ADULT; AGED; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DIABETIC PATIENT; DOWN REGULATION; DRUG MECHANISM; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE; MALE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL VALUE; OXIDATION REDUCTION STATE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN MODIFICATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TREATMENT RESPONSE;

ACETYLCYSTEINE; AGED; AGED, 80 AND OVER; CROSS-OVER STUDIES; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NF-KAPPA B; REFERENCE VALUES; RENAL DIALYSIS;

EID: 84880097153     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000167     Document Type: Article

References (53)

1. Luke RG. Chronic renal failure-a vasculopathic state. N Engl J Med. 1998;339:841-843.
2. Zoccali C. Cardiovascular risk in uraemic patients-is it fully explained by classical risk factors? Nephrol Dial Transplant. 2000;15:454-457.
3. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 2003;18(7):1272-1280.
4. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62: 1524-1538.
5. Amore A, Coppo R. Effect on the immune response. Oxford Textbook of Clinical Nephrology. 3rd ed. In: Davison AM et al, eds. Oxford: Oxford University Press 2005; 1868-1874
6. Descamps-Latscha B, Drüeke T, Witko-Sarsat V. Dialysisinduced oxidative stress: biological aspects, clinical consequences, and therapy. Semin Dial. 2001;14(3):193-199.
7. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial. 2002;15(5):329-337.
8. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002;23:599-622
9. Brownlee M. A radical explanation for glucose-induced Beta cell dysfunction. J Clin Invest. 2003;112:1788-1790.
10. Brownlee M, Cerami A. The biochemistry of the complications of diabetes mellitus. Annu Rev Biochem. 1981;50: 385-432.
11. Brownlee M. Negative consequences of glycation. Metabolism. 2000;49:9-13.
12. Wollf SP, Dean RT. Glucose autooxidation and protein modification. The potential role of "autooxidative glycosylation" in diabetes. Biochem J. 1987;245:243-250.
13. Amore A, Cirina P, Conti G, et al. Amadori-configurated albumin induces nitric oxide-dependent apoptosis of endothelial cells: a possible mechanism of diabetic vasculopathy. Nephrol Dial Transplant. 2004;19:53-60.
14. Amore A, Cirina P, Mitola S, et al. Nonenzymatically glycated albumin (Amadori adducts) enhances nitric oxide synthase activity and gene expression in endothelial cells. Kidney Int. 1997;51:27-35.
15. Mohamed AK, Bierhaus A, Schiekofer S, Tritschler H, Ziegler R, Nawroth PP. The role of oxidative stress and NF-kB activation in late diabetic complications. Biofactors. 1999;10:157-167.
16. Mercurio F, Manning AM. NF-kB as a primary regulator of the stress response. Oncogene. 1999;18:6163-6171.
17. Tibbles LA, Woodgett JR. The stress-activated protein kinase pathways. Cell Mol Life Sci. 1999;55:1230-1254.
18. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol. 1998;161:2524-2532.
19. Bergesio F, Monzani G, Ciuti R, et al. Total antioxidant capacity (TAC): is it an effective method to evaluate the oxidative stress in uraemia? J Biolumin Chemilumin. 1998;13(5): 315-319.
20. Menè P, Amore A. Apoptosis: potential role in renal diseases. Nephrol Dial Transplant. 1998;13(8):1936-1943.
21. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care. 2003;26:1589-1596.
22. Banday AA, Fazili FR, Lokhandwala MF. Oxidative stress causes renal dopamine D1 receptor dysfunction and hypertension via mechanisms that involve nuclear factorkappaB and protein kinase C. J Am Soc Nephrol. 2007;18: 1446-1457.
23. Oyama T, Miyasita Y, Watanabe H, Shirai K. The role of polyol pathway in high glucose-induced endothelial cell damages. Diabetes Res Clin Pract. 2006;73(3):227-234.
24. Kaneto H, Xu G, Song KH, et al. Activation of the hexosamine pathway leads to deterioration of pancreatic beta-cell function through the induction of oxidative stress. J Biol Chem. 2001;276:31099-31104.
25. Schleicher ED, Bierhaus A, Häring HU, Nawroth PP, Lehmann R. Chemistry and pathobiology of advanced glycation end products. Contrib Nephrol. 2001;131:1-9.
26. De Winther MP, Kanters E, Kraal G, Hofker MH. Nuclear factor kappaB signalling in atherogenesis. Arterioscler Thromb Vasc Biol. 2005;25:904-914.
27. Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in lowdensity lipoprotein receptor-deficient mice. Mol Cell. 1998;2: 275-281.
28. Aiello RJ, Bourassa PA, Lindsey S, et al. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 1999;19:1518-1525.
29. Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest. 2001;107:1255-1262.
30. Collins RG, Velji R, Guevara NV, Hicks MJ, Chan L, Beaudet AL. P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J Exp Med. 2000;191: 189-194.
31. Johnson RC, Chapman SM, Dong ZM, et al. Absence of P-selectin delays fatty streak formation in mice. J Clin Invest. 1997;99:1037-1043.
32. Epinat JC, Gilmore TD. Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway. Oncogene. 1999;18(49):6896-6909.
33. Vlassara H, Torreggiani M, Post JB, et al. Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging. Kidney Int Suppl. 2009;114:S3-11.
34. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation. 2003;107:992-995.
35. Tepel M. N-Acetylcysteine in the prevention of ototoxicity. Kidney Int. 2007;72(3):231-232.
36. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation. 2006; 113:1799-1806.
37. Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M. Acetylcysteine reduces homosysteine concentration and improves pulse pressure and endothelial function in patients with end stage renal failure. Circulation. 2004;109:369-374.
38. Thaha MW, Pranawa W, Yogiantoro M, Tomino Y. Intravenous N-acetylcisteine during hemodialysis reduces asymmetric dimethylarginine levels in end-stage renal disease patients. Clin Nephrol. 2008;69:24-32.
39. Zoccali C. Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move. J Hypertens. 2006; 24:611-619.
40. Huh JY, Seo EY, Lee HB, Ha H. Glucose-based peritoneal dialysis solution suppresses adiponectin synthesis through oxidative stress I an experimental model of peritoneal dialysis. Perit Dial Int. 2012;32(1):20-28.
41. Feldman L, Shani M, Efrati S et al. N-acetylcisteine improves residual renal function in peritoneal dialysis patients: a pilot study. Perit Dial Int. 2011;31(5):545-550.
42. Kuo HT, Lee JJ, Chen HW, Chen HC. N-acetylcisteine prevents mithocondria from oxidative injury induced by conventional peritoneal dialysate in peritoneal mesothelial cells. Am J Nephrol. 2009;30:179-185.
43. Nascimento MM, Suliman ME, Silva M et al. Effect of oral Nacetylcisteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebocontrolled study. Perit Dial Int. 2010;30:336-342.
44. Ruiz Fuentes MC, Moreno Ayuso JM, Ruin Funtes N, Vargas Palomares JF, Asensio Peinado C, Osuna Ortega A. Tratnment with N-acetylcisteine in stable renal transplantation. Transplant Proc. 2008;40:2897-2899.
45. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37-46.
46. Dagenais GR, Marchioli R, Yusuf S, Tognoni G. Beta-carotene, vitamin C, and vitamin E and cardiovascular diseases. Curr Cardiol Rep. 2000;2:293-299.
47. Galli F, Buoncristiani U, Conte C, Aisa C, Floridi A. Vitamin E in uremia and dialysis patients. Ann N Y Acad Sci. 2004; 1031:348-351.
48. Baragetti I, Furiani S, Vettoretti S, et al. Role of vitamin E-coated membrane in reducing advanced glycation end products in hemodialysis patients: a pilot study. Blood Purif. 2006;24: 369-376.
49. Libetta C, Zucchi M, Gori E, et al. Vitamin E-loaded dialyzer resets PBMC-operated cytokine network in dialysis patients. Kidney Int. 2004;65:1473-1481.
50. Sosa MA, Balk EM, Lau J, et al. A systematic review of the effect of the Excebrane dialyser on biomarkers of lipid peroxidation. Nephrol Dial Transplant. 2006;21:2825-2833.
51. Palacio JR, Market UR, Martinez P. Anti-inflammatory properties of N-acetylcysteine on lipopolysaccharide-activated macrophages. Inflamm Res. 2011;60:695-704.
52. Nascimento MM, Suliman ME, Silva M et al. Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebocontrolled study. Perit Dial Int. 2010;30:336-342.
53. Guo Z, Xia Z, Jiang J, Mcneill JH. Downregulation of NA-DPH oxidase, antioxidant enzymes, and inflammatory markers in the heart of streptozocin-induced diabetic rats by N-acetylcysteine. Am J Physiol Hearth Circ Physiol. 2007; 292:H1728-1736.